Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9Y235
UPID:
ABEC2_HUMAN
Alternative names:
mRNA(cytosine(6666)) deaminase 2
Alternative UPACC:
Q9Y235; B2R899; Q53F28; Q5TGU5; Q5TGU6
Background:
C->U-editing enzyme APOBEC-2, also known as mRNA(cytosine(6666)) deaminase 2, is a probable C to U editing enzyme with a yet unidentified physiological substrate. It does not exhibit apoB mRNA editing but has a low intrinsic cytidine deaminase activity. This enzyme may play a crucial role in the epigenetic regulation of gene expression through active DNA demethylation.
Therapeutic significance:
Understanding the role of C->U-editing enzyme APOBEC-2 could open doors to potential therapeutic strategies.